These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12731424)

  • 1. [Reduction of cardiovascular events with lorsartan? The LIFE Study].
    Schunkert H
    Internist (Berl); 2003 Mar; 44(3):367-70. PubMed ID: 12731424
    [No Abstract]   [Full Text] [Related]  

  • 2. [Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
    MMW Fortschr Med; 2002 Sep; 144(38):14. PubMed ID: 12395694
    [No Abstract]   [Full Text] [Related]  

  • 3. [German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
    Dominiak P; Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):47. PubMed ID: 12395703
    [No Abstract]   [Full Text] [Related]  

  • 4. [What are the consequences of the LIFE Study for general practice].
    Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704
    [No Abstract]   [Full Text] [Related]  

  • 5. [Losartan in isolated systolic hypertension--convincing results of a LIFE sub-group study].
    MMW Fortschr Med; 2003 Jan; 145(1-2):50-1. PubMed ID: 12638440
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
    Bourassa MG
    J Am Coll Cardiol; 2005 Mar; 45(5):720-1. PubMed ID: 15734616
    [No Abstract]   [Full Text] [Related]  

  • 7. [Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
    MMW Fortschr Med; 2002 May; 144(20):60-1. PubMed ID: 12119887
    [No Abstract]   [Full Text] [Related]  

  • 8. Was the LIFE trial independent?
    Vandenbroucke JP
    Lancet; 2002 Oct; 360(9340):1171; author reply 1171. PubMed ID: 12387974
    [No Abstract]   [Full Text] [Related]  

  • 9. Was the LIFE trial independent?
    Van Brabandt H
    Lancet; 2002 Oct; 360(9340):1171; author reply 1171. PubMed ID: 12387973
    [No Abstract]   [Full Text] [Related]  

  • 10. Implications of the LIFE trial.
    Nadar S; Lim HS; Lip GY
    Expert Opin Investig Drugs; 2003 May; 12(5):871-7. PubMed ID: 12720497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
    Einecke D
    MMW Fortschr Med; 2002 Apr; 144(14):4-5. PubMed ID: 12014276
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristiansson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H;
    Lancet; 2002 Mar; 359(9311):995-1003. PubMed ID: 11937178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Lindholm LH; Ibsen H; Dahlöf B; Devereux RB; Beevers G; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Kristiansson K; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wedel H; Aurup P; Edelman J; Snapinn S;
    Lancet; 2002 Mar; 359(9311):1004-10. PubMed ID: 11937179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
    Devereux RB; Dahlöf B; Kjeldsen SE; Julius S; Aurup P; Beevers G; Edelman JM; de Faire U; Fyhrquist F; Helle Berg S; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
    Ann Intern Med; 2003 Aug; 139(3):169-77. PubMed ID: 12899584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group.
    Farsang C; Garcia-Puig J; Niegowska J; Baiz AQ; Vrijens F; Bortman G
    J Hypertens; 2000 Jun; 18(6):795-801. PubMed ID: 10872566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
    Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
    JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
    Schiffrin EL; Park JB; Intengan HD; Touyz RM
    Circulation; 2000 Apr; 101(14):1653-9. PubMed ID: 10758046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.